Enliven Therapeutics, Inc. 13D

OrbiMed Advisors LLC and affiliates now hold about 10.93% of Enliven Therapeutics, Inc., have reduced their beneficial stake by more than 1% mainly due to dilution and transactions, and indicate a non-activist, opportunistic investment stance with potential future buying or selling.

OrbiMed Advisors LLC and affiliated funds report in Amendment No. 4 to their Schedule 13D on Enliven Therapeutics, Inc. that they beneficially own approximately 7,634,630 shares, or about 10.93% of the company’s outstanding common stock (primarily via OrbiMed Private Investments VII, LP), reflecting a decrease of more than 1% in ownership due to a combination of disclosed transactions and an increase in Enliven’s shares outstanding; they characterize the position as a flexible financial investment, with no specific activist or control-related plans, and state that they may buy or sell shares over time depending on market conditions and the issuer’s prospects.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

13D

Source Type

sec

Accession

0000947871-26-000636

Alert Tier

7